Erasca is a clinical-stage precision oncology company driven by a bold mission—to erase cancer. We are on a journey to shut down one of cancer’s most commonly mutated signaling cascades, the RAS/MAPK pathway, which affects approximately 5.5 million lives each year worldwide. Our promising pipeline targets the RAS/MAPK pathway at virtually every turn, endowing us with the potential to make a transformative difference in the treatment and lives of people suffering from a wide range of devastating cancers—bringing hope, where there was little, that the future can be brighter and cancer free.
09. 22. 2021Erasca Announces First Patient Dosed in HERKULES-3, a Phase 1b/2 Gastrointestinal Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations
09. 09. 2021Erasca Announces First Patient Dosed in HERKULES-2 Phase 1b/2 Lung Cancer Master Protocol Evaluating ERAS-007 in Multiple Combinations